PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2010; 5(8): e12381.
Published online 2010 August 26. doi:  10.1371/journal.pone.0012381
PMCID: PMC2928722

Does the KIR2DS5 Gene Protect from Some Human Diseases?

Jacques Zimmer, Editor

Abstract

Background

KIR2DS5 gene encodes an activating natural killer cell receptor whose ligand is not known. It was recently reported to affect the outcome of hematopoietic stem cell transplantation.

Methodology/Principal Findings

In our studies on KIR2DS5 gene associations with human diseases, we compared the frequencies of this gene in patients and relevant controls. Typing for KIR2DS5 gene was performed by either individual or multiplex polymerase chain reactions which, when compared in the same samples, gave concordant results. We noted an apparently protective effect of KIR2DS5 gene presence in several clinical conditions, but not in others. Namely, this effect was observed in ankylosing spondylitis (p = 0.003, odds ratio [OR] = 0.47, confidence interval [CI] = 0.28–0.79), endometriosis (p = 0.03, OR = 0.25, CI = 0.07–0.82) and acute rejection of kidney graft (p = 0.0056, OR = 0.44, CI = 0.24–0.80), but not in non-small-cell lung carcinoma, rheumatoid arthritis, spontaneous abortion, or leukemia (all p>0.05). In addition, the simultaneous presence of KIR2DS5 gene and HLA-C C1 allotype exhibited an even stronger protective effect on ankylosing spondylitis (p = 0.0003, OR = 0.35, CI = 0.19–0.65), whereas a lack of KIR2DS5 and the presence of the HLA-C C2 allotype was associated with ankylosing spondylitis (p = 0.0017, OR = 1.92, CI = 1.28–2.89), whereas a lack of KIR2DS5 and presence of C1 allotype was associated with rheumatoid arthritis (p = 0.005, OR = 1.47, CI = 1.13–1.92). The presence of both KIR2DS5 and C1 seemed to protect from acute kidney graft rejection (p = 0.017, OR = 0.47, CI = 0.25–0.89), whereas lack of KIR2DS5 and presence of C2 seemed to favor rejection (p = 0.0015, OR = 2.13, CI = 1.34–3.37).

Conclusions/Significance

Our results suggest that KIR2DS5 may protect from endometriosis, ankylosing spondylitis, and acute rejection of kidney graft.

Introduction

Killer immunoglobulin-like two-domain short-tail receptor 5 (KIR2DS5) is a member of a large KIR family of cell-surface receptors expressed on natural killer (NK) cells and subpopulations of T lymphocytes. In contrast to long cytoplasmic tail-possessing KIRs (KIR2DL and KIR3DL), which inhibit cell activation upon ligand binding, KIRs with short cytoplasmic tails (KIR3DS1 and KIR2DS, including KIR2DS5) activate cells expressing them. Ligands (HLA class I molecules) are known only for some KIRs (HLA-C alleles from the C1 group [Asn80] for KIR2DL2 and KIR2DL3; HLA-C alleles from the C2 group [Lys80] for KIR2DL1 and KIR2DS1; HLA-B from the Bw4 group for KIR3DL1 and possibly KIR3DS1; HLA-A*03, *11 for KIR3DL2), whereas no physiological ligands are known for the remaining KIRs, including KIR2DS5 [1], [2]. Nevertheless, the effects of KIR2DS5 gene presence or absence in the context of HLA-C C1 or C2 or both were recently observed in bone marrow transplantation [3]. Upon our studies on the associations of KIR genes with a panel of autoimmune, gynecological, and neoplastic diseases as well as in the acute rejection of kidney graft, we observed effects of KIR2DS5 gene and HLA-C C1 and C2 groups in some of these clinical situations. A protective effect of KIR2DS5 gene on susceptibility to psoriasis vulgaris was already described elsewhere [4]. Other results are presented here.

Results

The frequencies of KIR2DS5 gene in autoimmune and neoplastic diseases as well as in renal transplant rejection were compared with its frequency in a representative population of 690 healthy unrelated Poles (Control I, see Materials and Methods). Significant differences were found in only two clinical situations, ankylosing spondylitis (AS) and acute rejection of kidney graft (Table 1). In both instances a decrease in KIR2DS5 frequency was observed. However, only AS result was still significant after Bonferroni correction (pc = 0.033). No significance was found in comparisons between controls (Control I) and patients with rheumatoid arthritis (RA), stable kidney graft function, and neoplastic diseases such as non-small-cell lung carcinoma (NSCLC), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML).

Table 1
Frequencies of KIR2DS5 gene in different diseases.

KIR2DS5 frequency in endometriosis was compared with that in healthy women who had delivered at least one healthy baby (Control II). Again, it was less frequent in the patients than in the controls (Table 1).

Women suffering from spontaneous abortion were compared with healthy women who had delivered at least two healthy children (Control III). No significant difference between these two groups was detected in frequencies of KIR2DS5 gene (Table 1).

HLA-C C1 and C2 phenotype and genotype frequencies were significantly different from controls in ankylosing spondylitis (i.e. a decrease in C1 frequency) (Table 2). Moreover, C1C2 heterozygosity was less frequent in non-small-cell lung carcinoma patients (significant difference from the control, Table 2). However, both differences lost significance after correction.

Table 2
Frequencies of HLA-C C1 and C2 gene groups in different diseases.

In addition, the analysis of combinations of the presence of KIR2DS5 with the two HLA-C groups revealed several interesting results (see Table 3 for raw data and Table 4 for statistical analysis). In KIR2DS5-positive AS patients the frequencies of the HLA-C C1 phenotype were significantly lower than in Control I, and this was the only result in Table 4 which persisted significant after correction (pc = 0.033). In AS, the C1C2 genotype was three times less frequent than in the controls. In contrast, the C2 phenotype frequency was decreased in endometriosis in comparison with Control II.

Table 3
Frequencies of KIR2DS5 gene and C1 and C2 groups of HLA-C in several human diseases and healthy control individuals.
Table 4
Statistical analysis of the data from Table 3 (KIR2DS5, C1 and C2 frequencies).

Similarly, in the absence of KIR2DS5, the C1 and C2 phenotypes were significantly associated with several clinical conditions. Thus C1 frequencies were increased in RA and kidney graft rejection, whereas those of C2 were increased in AS, and kidney rejection. C1C2 heterozygosity was increased in RA and kidney rejection.

No differences in the distributions of C1 and C2 phenotypes and genotypes combined with the presence or absence of KIR2DS5 were observed in kidney graft nonrejectors (Tables 3 and and4)4) or patients with malignancies (ALL, AML, CML, and NSCLC; data not shown). The same was true for spontaneous abortion couples compared with Control III (data not shown).

Discussion

Our results suggest that the presence of KIR2DS5 gene may protect against some clinical conditions. In addition to psoriasis vulgaris described earlier [4], such protection was observed in endometriosis, ankylosing spondylitis, and acute rejection of kidney graft. In women with endometriosis, in contrast to healthy ones, ectopic endometrium is thought to be inefficiently eliminated by NK cells which exhibit insufficient cytotoxic activity in these patients [5], [6]. Therefore, a contribution of activating KIR2DS5 receptor to protection against endometriosis seems likely.

In contrast, an explanation of the apparently paradoxical protective effect of a killer cell-activating receptor in autoimmune disease (ankylosing spondylitis) and acute transplant rejection is more difficult. NK cells have been postulated to contribute to allograft tolerance induction [7], [8]. Therefore we may speculate that the presence of KIR2DS5 contributes to the activation of NK cells, leading to a more efficient induction of tolerance and inhibition of allograft rejection and autoimmunity. In contrast, lack of KIR2DS5 would weaken NK cell activation, resulting in insufficient induction of tolerance and in the promotion of acute kidney allograft rejection or autoaggression, for example in ankylosing spondylitis. It should be noted here, however, that in HLA-B27-positive Chinese patients with ankylosing spondylitis, KIR2DS5 was associated rather with susceptibility than with protection compared with HLA-B27-positive controls [9], whereas it was not associated with this disease in HLA-unselected Chinese patients compared with unselected controls [10]. However, Chinese are genetically distant from Caucasians, as reflected, for example, by the difference in distribution of HLA-B27 subtypes (alleles) in these two populations [11], [12], and indeed, neither KIR3DL1/KIR3DS1 [13] nor KIR2DS5 [9] effects on AS in Chinese could be reproduced in some Caucasian populations [14], although they were observed in other Caucasians [15], [16]. In our study, we have not seen any association of KIR3DL1, putative receptor of HLA-B27 [17], [18], and only weak association of KIR3DS1, with ankylosing spondylitis (data not shown). This may speak against linkage disequilibrium (LD) of KIR2DS5 with other KIRs as a main cause of its protective effect in AS.

One might argue that the apparent effect of KIR2DS5 in other diseases might be caused by its LD with other KIR2D genes whose products bind HLA-C molecules, distinguishing between C1 and C2 epitopes [1], [2]. Indeed, kidney graft rejection seems to be associated in Poles with KIR2DS4 full length gene (our unpublished data), which is in negative LD with KIR2DS5 in many human populations including European Caucasians [19]. Therefore, the apparent protective effect of KIR2DS5 described here for kidney rejection may result from this LD. On the other hand, only KIR2DS5 gene was (negatively) associated with susceptibility to endometriosis, and KIR2DS4 deletion variant was less frequent in peritoneal form of this disease (our unpublished data). This finding speaks against LD as an explanation for KIR2DS5 protective effect in endometriosis because KIR2DS4 and KIR2DS5 are mutually exclusive in most haplotypes [19].

We also observed effects of HLA-C C1 and C2 genotypes in some diseases. We found an association with C2 homozygosity in ankylosing spondylitis, which seems to be concordant with results in Chinese, where an association of the HLA-Cw*02 allele (a member of the C2 group) with this disease was described [9]. We can not exclude LD of C2 with HLA-B27 as a main cause of this association, as most HLA-B*27 carriers in Caucasian populations have HLA-Cw*02 [20]. Another finding was that C1C2 heterozygosity seemed to protect from NSCLC. Although no data have been published on an association between NSCLC and HLA-C so far, we may speculate that the C1C2 genotype may allow for a wider spectrum of KIRs to contribute to control over cancer cells.

Additionally, we observed that in some diseases, the effect of C1 and C2 phenotypes or genotypes seemed to be detectable only in the absence of KIR2DS5 gene but was visible only in its presence in other diseases. However, these results are easily explainable by the protective effect of KIR2DS5 alone. For example, both the C1 and the C2 frequencies were reduced in AS patients positive for KIR2DS5, whereas both were increased in KIR2DS5-negative patients.

In summary, our results suggest protective effect of the presence of KIR2DS5 gene in ankylosing spondylitis, endometriosis and acute kidney graft rejection, independent from HLA-C. Some KIR2DS5-independent associations of ankylosing spondylitis and NSCLC with HLA-C C1 and/or C2 groups are also reported here. To our knowledge, this is the first report on possible associations of non-small cell lung cancer with KIR and HLA-C genes.

Materials and Methods

Participants

Three hundred and sixty-six patients with rheumatoid arthritis (280 women, 64 men; mean age, 57.8±12.3, range 22–90) were recruited from the inpatient and outpatient population of the Clinic of Rheumatology and Internal Diseases, Autonomous Public Clinical Hospital No. 1, Pomeranian Medical University in Szczecin, Poland, and diagnosed according to the criteria of the American College of Rheumatology as described previously [21].

Two hundred and eighty patients (80 women and 200 men, mean age 62.06±9.3, range 35–87 years) with pathologically documented non-small-cell lung carcinoma (NSCLC) were qualified in the Department of Pulmonology and Lung Cancer, Wroclaw Medical University, and in the Clinic of Lung and Thorax Neoplasms, Centre of Oncology – Maria Skłodowska-Curie Institute, Warsaw. The diagnosis of lung cancer was based on positive histological or cytological examination (according to WHO criteria) [22]. A fibro-bronchoscopic examination was performed in all the patients, with harvesting of material for histological and cytological examination for establishing a diagnosis of NSCL. All participants underwent a sputum cytology survey as well. Advancement of the disease was determined according to the TNM staging system; thoracic computed tomography involving the upper abdomen was used for this purpose.

Two hundred and eighty-five adult cadaveric donor renal transplant recipients (123 women, 162 men; mean age, 43.43±11.44 years, range, 15–72) from the Department of Nephrology and Transplantation Medicine, Wrocław Medical University, who had undergone primary transplantation between 1989 and 2008 were included in the study; mean time of follow-up was 7 years. All patients received conventional immunosuppression: cyclosporine or tacrolimus in combination with azathioprine or mycofenolate mofetil and steroids. They were divided into two groups according to the occurrence of an acute rejection episode: 89 patients with an acute rejection episode and 196 patients without. Acute rejection was defined by an increase in serum creatinine level of at least 20% above the baseline measurements (not attributable to another cause) and confirmed by biopsy according to the Banff histopathological criteria [23]. Apart from three patients, all had a biopsy-confirmed acute rejection episode.

One hundred and fifteen patients (18 women, 83 men; age data for 101 patients were available: mean age, 36.7±14.5 years; range, 18–71) were diagnosed as definite ankylosing spondylitis in accordance with the modified New York classification criteria [24] at the Department of Rheumatology III, Silesian Hospital of Rheumatology and Rehabilitation, Ustroń, or at the Department and Clinic of Rheumatology and Internal Medicine, Wrocław Medical University. Ninety percent of the patients were HLA-B*27 positive by either serological or genetic typing (data not shown), in agreement with other populations [12].

Ninety-six patients treated with allogeneic hematopoietic stem cell transplant in the Department of Hematology and Bone Marrow Transplantation of the Silesian Medical University in Katowice because of leukemia (53 women, 43men; mean age, 33.3±10.9 years; including acute lymphoblastic leukemia, ALL, 22 patients, 11 women, 11 men; mean age, 27.4±9.7; acute myeloid leukemia, AML, 40 patients, 26 women, 14 men; mean age, 36.9±12.1; chronic myeloid leukemia, CML, 34 patients, 16 women, 18 men; mean age, 33.1 years) were described elsewhere [25].

Six hundred and ninety unrelated healthy volunteers (355 women, 335 men; mean age, 38.62±14.60, range, 19–56) were recruited in the years 2001–2008 by the Regional Center of Blood Transfusion, Wrocław, as well as by clinics of the Wrocław Medical University, the Medical University of Warsaw, and the Pomeranian Medical University, Szczecin (Control I, used for the diseases mentioned above).

One hundred and fifty-three women with endometriosis (mean age 33.7±8.0, range 20–58 years) diagnosed at the First and Second Departments of Obstetrics and Gynecology, Medical University of Warsaw, for pelvic pains, dysmenorrhea, and/or infertility were described in detail elsewhere [26]. Endometriosis had been confirmed and classified in these patients by both laparoscopic and histopathological examinations according to the revised American Fertility Society criteria [27]. Two hundred and thirteen healthy women who had given birth to at least one child were used as a control (Control II; this group included women from Control III described below and was included in Control I).

One hundred forty-nine couples (mean age of women: 32.44±4.21 years, range: 24–46) who had experienced spontaneous abortion (SA) were recruited for our study at the Polish Mother's Memorial Hospital - Research Institute, Łódź, the First Chair and Clinic of Obstetrics and Gynecology, Medical University of Warsaw, and the Institute of Human Genetics, Polish Academy of Sciences, Poznań. The criteria for patient classification and inclusion were presented elsewhere [28]. For a control (“Control III”), 117 healthy couples (mean age of women: 31.37±6.36, range: 23–68 years) with at least two healthy-born children and no history of abortion were included (Wrocław Medical University and Medical University of Warsaw).

DNA isolation and KIR2DS5 and HLA-C C1/C2 group typing

Genomic DNA was isolated from venous blood as described elsewhere [21], [29]. KIR2DS5 was typed by either individual [29] or multiplex [30] polymerase chain reactions which, when compared in the same samples, gave concordant results. It should be noted here that our KIR typing is validated three times per year by the International KIR Exchange program organized by the Immunogenetics Center of the University of California at Los Angeles. HLA-C groups C1 and C2 were established as described by Frohn et al. [31].

Ethics

This project was accepted by the Bioethics Committee of the Medical University of Warsaw, the Bioethics Committee of the Wrocław Medical University, the Bioethics Committee of the Pomeranian Medical University in Szczecin, the Bioethics Committee of the Polish Mother's Memorial Hospital - Research Institute in Łódź, the Bioethics Committee of the Silesian Medical University in Katowice, and the Bioethics Committee of the Medical University of Poznań. Signed informed consent was given by all participants. Ludwik Hirszfeld Institute of Immunology and Experimental Therapy has no Bioethic Committee for research on human materials, and our projects are evaluated by the Bioethics Committee of the Wrocław Medical University. The same applies to the Silesian Hospital of Rheumatology and Rehabilitation which needs approval from the Bioethics Committee of the Silesian Medical University in Katowice. Approval from the Bioethics Committee of the Institute of Oncology in Gliwice was not required, as no samples originated from that institution.

Statistical methods

Differences between controls, patients, and patient subgroups were estimated using the two-tailed Fisher's exact test and GraphPad InStat 3 software. A p value<0.05 was considered significant. The Bonferroni correction of p-values (if<0.05) was calculated for the number of comparisons (11 for Table 1, 45 for Table 2, and 70 for Table 3). Statistical power was calculated post-hoc for alpha error level = 0.05.

Acknowledgments

We would like to thank our patients and healthy volunteers for donating blood for our study. We also thank Dr. Katarzyna Zajda for collection of patient blood samples and Agnieszka Kowal, Maciej Miazga and Marta Wagner for their generous help in KIR typing and data analysis. Technical assistance of Daria Gendosz and Elżbieta Wiśniewska is gratefully acknowledged.

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported by grants N402 078 31/2416, N401 077 31/1819, 2P05A 069 28, and 2 PO5B 155 28 from the Polish Ministry of Science and Higher Education. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Cheent K, Khakoo SI. Natural killer cells: integrating diversity with function. Immunology. 2009;126:449–457. [PubMed]
2. Middleton D, Gonzelez F. The extensive polymorphism of KIR genes. Immunology. 2009;129:8–19. [PubMed]
3. van der Meer A, Schaap NPM, Schattenberg AVMB, van Cranenbroek B, Tijssen HJ, et al. KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients. Molec Immunol. 2008;45:3631–3638. [PubMed]
4. Płoski R, Łuszczek W, Kuśnierczyk P, Nockowski P, Cisło M, et al. A role for KIR gene variants other than KIR2DS1 in conferring susceptibility to psoriasis. Hum Immunol. 2006;67:521–526. [PubMed]
5. Berkkanoglu M, Arici A. Immunology and endometriosis. Am J Reprod Immunol. 2003;50:48–59. [PubMed]
6. Ulukus M, Arici A. Immunology of endometriosis. Minerva Ginecol. 2005;57:237–48. [PubMed]
7. Beilke JN, Gill RG. Frontiers in nephrology: The varied faces of natural killer cells in transplantation – contribution to both allograft immunity and tolerance. J Am Soc Nephrol. 2007;18:2262–2267. [PubMed]
8. Zenhaeusem G, Gasser O, Hönger G, Durovic B, Stern M, et al. Regulatory allospecific NK cell function is differentially associated with HLA-C allotypes. Am J Transplant. 2009;9:2624–2630. [PubMed]
9. Diaz-Pena R, Blanco-Gelaz MA, Suarez-Alvarez B, Martínez-Borra J, López-Vázquez A, et al. Activating KIR genes are associated with ankylosing spondylitis in Asian populations. Hum Immunol. 2008;69:437–442. [PubMed]
10. Jiao Y-L, Ma C-Y, Wang L-C, Cui B, Zhang J, et al. Polymorphisms of KIRs gene and HLA-C alleles in patients with ankylosing spondylitis: Possible association with susceptibility to the disease. J Clin Immunol. 2008;28:343–349. [PubMed]
11. Middleton D, Menchaca L, Rood H, Komerofsky R. New Allele Frequency Database. Tissue Antigens. 2003;61:403–407. Available: http://www.allelefrequencies.net. [PubMed]
12. Reveille JD. Recent studies on the genetic basis of ankylosing spondylitis. Curr Rheumatol Reports. 2009;11:340–348. [PubMed]
13. Lopez de Castro JA. HLA-B27 and ankylosing spondylitis: tales from China. Tissue Antigens. 2010;75:9–11. [PubMed]
14. Diaz-Pena R, Vidal-Castineira JR, Alonso-Arias R, Suarez-Alvarez B, Vicario JL, et al. Association of the KIR3DS1*013 and KIR3DL1*004 alleles with susceptibility to ankylosing spondylitis. Arthritis Rheum. 2010;62:1000–1006. [PubMed]
15. McCappin J, Harvey D, Wordsworth BP, Middleton D. No association of KIR3DL1 or KIR3DS1 or their alleles with ankylosing spondylitis. Tissue Antigens. 2009;75:68–73. [PubMed]
16. Lopez-Larrea C, Blanco Gelaz MA, Torre-Alonso JC, Bruges Armas J, Suarez-Alvarez B, et al. Contribution of KIR3DL1/3DS1 to ankylosing spondylitis in human leukocyte antigen-B27 Caucasian populations. Arthritis Res Ther. 2006;8:R101. [PMC free article] [PubMed]
17. Allen RL, Raine T, Haude A, Trowsdale J, Wilson MJ. Leukocyte receptor comlex-encoded immunomodulatory receptors show differing specificity for alternative HLA-B27 structures. J Immunol. 2001;15:5543–5547. [PubMed]
18. Kollnberger S, Chan A, Sun MY, Chen LY, Wright C, et al. Interaction of HLA-B27 homodimers with KIR3DL1 and KIR3DL2, unlike HLA-B27 heterodimers, is independent of the sequence of bound peptide. Eur J Immunol. 2007;37:1313–1322. [PubMed]
19. Single RM, Martin MP, Meyer D, Gao X, Carrington M. Methods for assesing gene content diversity of KIR with examples from a global of populations. Immunogenetics. 2008;60:711–725. [PMC free article] [PubMed]
20. Ahmad T, Neville M, Marshall SE, Armuzzi A, Mulcahy-Hawes K. Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC. Hum Mol Genet. 2003;12:647–656. [PubMed]
21. Majorczyk E, Pawlik A, Łuszczek W, Nowak I, Wiśniewski A, et al. Associations of killer cell immunoglobulin-like receptor genes with complications of rheumatoid arthritis. Genes Immunity. 2007;8:678–683. [PubMed]
22. World Health Organization. International classification of tumors, No. 1, 2nd edition. Geneva: World Health Organization; 1981. Histological typing of lung cancer tumours.
23. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, et al. The Banff 97 working classification of renal allograft pathology. Kidney Intern. 1999;55:713–723. [PubMed]
24. van den Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–368. [PubMed]
25. Giebel S, Nowak I, Dziaczkowska J, Czerw T, Wojnar J, et al. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus host disease and affect survival after allogeneic hematopoietic stem cell transplantation. Eur J Haematol. 2009;83:343–356. [PubMed]
26. Płoski R, Dziunycz P, Kostrzewa G, Roszkowski PI, Barcz E, et al. PTPN22/LYP 1858C>T gene polymorphism and susceptibility to endometriosis in a Polish population. J Reprod Immunol. 2009;79:196–200. [PubMed]
27. Canis M, Donnez JG, Guzick DS, Halme JK, Rock JA, et al. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertility and Sterility. 1997;67:817–821. [PubMed]
28. Nowak I, Malinowski A, Tchórzewski H, Barcz E, Wilczyński JR, et al. Frequencies of killer immunoglobulin-like receptor genotypes influence susceptibility to spontaneous abortion. J Appl Genet. 2009;50:391–398. [PubMed]
29. Łuszczek W, Mańczak M, Cisło M, Nockowski P, Wiśniewski A, et al. Gene for the activating natural killer cell receptor, KIR2DS1, is associated with susceptibility to psoriasis vulgaris. Hum Immunol. 2004;65:758–766. [PubMed]
30. Sun JY, Gaidulis L, Miller MM, Goto RM, Rodriguez R, et al. Development of a multiplex PCR-SSP method for killer-cell immunoglobulin-like receptor genotyping. Tissue Antigens. 2004;64:462–468. [PubMed]
31. Frohn C, Schlenke P, Ebel B, Dannenberg C, Bein G, et al. DNA typing for natural killer cell inhibiting HLA-Cw groups NK1 and NK2 by PCR-SSP. J Immunol Meth. 1998;218:155–160. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science